[Expression of CD44-standard in 182 primary neuroblastomas].
182 untreated neuroblastomas were examined for the expression of the adhesion molecule CD44s by immunohistochemistry; all tumors were also tested for amplification of the oncogene N-myc by conventional Southern blot analyses. Positive CD44s immunoreactivity correlated not with a more favorable prognosis in contrast to an absence of CD44s expression in stage dependent or independent evaluations. All patients with stage 4S disease (n = 16) expressed CD44s on a high level and had an event-free survival probability of 82%. In undifferentiated neuroblastoma subgroups could be defined, depending on the expression of CD44s (p < 0.01). In 93% of N-myc non-amplified tumors CD44s expression was detected, whereas only 62% of N-myc amplified tumors were positive for CD44s expression. These results point to CD44s expression as a new histological marker in neuroblastoma, having prognostic impact in tumors of undifferentiated morphology.
Christiansen
H
H
Abteilung Allgemeine Pädiatrie, Hämatologie und Onkologie, Universität Giessen.
Terpe
H J
HJ
Gonzales
M
M
Wenderhold
S
S
Berthold
F
F
Lampert
F
F
D014408:Biomarkers, Tumor / Q000235:genetics*; D015139:Blotting, Southern; D002648:Child; D018572:Disease-Free Survival; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics*; D007124:Immunoenzyme Techniques; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D015996:Survival Rate
D014408:Biomarkers, Tumor; D018960:Hyaluronan Receptors; D016271:Proto-Oncogene Proteins c-myc
Expression von CD44-Standard bei 182 primären Neuroblastomen.